Journal
THERAPEUTIC ADVANCES IN HEMATOLOGY
Volume 5, Issue 6, Pages 197-210Publisher
SAGE PUBLICATIONS LTD
DOI: 10.1177/2040620714552614
Keywords
histone deacetylase inhibitor; multiple myeloma; panobinostat
Categories
Funding
- Novartis
Ask authors/readers for more resources
Panobinostat is an investigational and potent histone deacetylase inhibitor (HDACi) that has shown promise as an antimultiple myeloma agent in the preclinical setting. In this review, we discuss the rationale for the use of panobinostat as a combination therapy for multiple myeloma and provide an overview of recent and ongoing clinical trials testing the safety and efficacy of panobinostat for the treatment of the disease.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available